Massachusetts General Hospital (MGH)
Nabeel Bardeesy, PhD
- Associate Professor of Medicine at Harvard Medical School
- Faculty at the MGH Center for Cancer Research
- Affiliated Faculty at the MGH Center for Regenerative Medicine
12 postdoctoral fellows, technicians, and students
The laboratory has worked to develop experimental models to better understand cholangiocarcinoma and predict potential new treatment approaches
Message to Patients
- As a CCF Scientific Advisory Board Member and cholangiocarcinoma researcher, Dr. Bardeesy would like to convey the message to patients that there is a rapidly growing community of scientists who are focusing on this cancer. Significant advances have been made in identifying and understanding the mutations that cause this cancer. This information has led to clinical trials that are showing promise.
- While much more needs to be done, the basic foundations in knowledge and model systems will continue to draw investigators to the field, and undoubtedly accelerate progress in the area.
CCF Funded Research
$50,000 – 2017 Andrea Scott Memorial Research Fellowship
Identifying Therapeutic Strategies for FGFR inhibition in Intrahepatic Cholangiocarcinoma Goal: To study the FGFR mutation to identify treatments that increase patient survival
$50,000 – 2016 Andrea Marie Fuquay Memorial Research Fellowship
2-HG as a Biomarker in Patients with IDH-mutant Intrahepatic Cholangiocarcinoma Goal: To compare new biomarkers to CA19-9 for diagnosing, monitoring, and predicting survival in patients with the IDH mutation
$60,000 – 2013 Conquer Cancer Young Investigator Award
Mutant IDH Inhibits HNF-4a to Block Hepatocyte Differentiation and Promote Biliary Cancer Goal: To develop animal models, including gene mutations, to better understand cholangiocarcinoma in humans
CCF Funded Research Publications
- Mass. General Team Identifies Mechanisms Behind Resistance to FGFR Inhibitor Drug Cancer Discovery, March 2017
- Clinical Features and Tumor Mutational Profile of Younger vs Older Patients with Cholangiocarcinoma Gastrointestinal Cancers Symposium, San Francisco, January 2017
- Consensus Treatment Guidelines for Urgent Symptoms in CCA Patients with Biliary Stents Using the Modified Rand/UCLA Delphi Process Gastrointestinal Cancers Symposium, San Francisco
- Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma Cancer Discovery, July 2016
- Mutant IDH Inhibits HNF-4a to Block Hepatocyte Differentiation and Promote Biliary Cancer Nature, VOL. 513, NO. 7516, 2014
Dr. Bardeesy considers the training of more than 10 postdoctoral fellows who now have established their own laboratories at major research universities or pharmaceutical companies focusing on cancer biology and therapeutics as his most important contribution to science.
Like many researchers, Dr. Bardeesy’s greatest challenges relate to the current funding climate. The federal government has traditionally been the most important source of research support in the U.S., and the budgets over the past many years have not matched the rising costs of doing biomedical research. Moreover, since cholangiocarcinoma is considered a rare cancer, there is an additional challenge in competing for funding with grant applications on cancer types thought to be of greater priority.
Nabeel Bardeesy, PhD
“By supporting innovative studies of cholangiocarcinoma by young cancer researchers, the Cholangiocarcinoma Foundation has made truly outstanding contributions to the field of cholangiocarcinoma research.”
Lei Shi, PhD
“With the generous support from the Cholangiocarcinoma Foundation, I am excited to investigate what fuels cancer cell growth and tumor formation in cholangiocarcinoma, which will help us to develop innovative drugs to improve treatment options.”